Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-19
    E.g., 2018-02-19

Articles

171562 items
12:00 AM, Aug 02, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Cellex sales and marketing update

CLXX entered into a distribution agreement under which ReceptorTechnologies Ltd. will marketing CLXX's Verax product line in England and Ireland. Verax uses fluidized bed cell cultures for the growth of certain types of cells such...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Hemagen regulatory update

HMGN received FDA clearance to market an assay that detects antibodies to cardiolipin. The assay can be used to diagnose and manage connective tissue diseases such as lupus. Peter von Stein, COO, said first shipments...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Trinity regulatory update

HIVSY received approval in Ireland for the sale of its HIV 1/2 SalivaCard and HIV 1/2 SeroCard as medical diagnostic kits for in vitro use. The certification includes the approval to export both products. HIVSY...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Schering-Plough regulatory update

Schering-Plough's subsidiary, DNAX Research Institute, has been issued U.S. Patent No. 5,231,012 covering the recombinant manufacture of human interleukin-10, a cytokine that supresses the immune system's inflammatory response. Schering-Plough Corp.   ...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Biomatrix sales and marketing update

BIOX licensed Hylashield, its hyaluronan ocular treatment, to Domilens Inc. for the treatment of ocular surface disorders in Canada. BIOX said Domilens will sell Hylashield without prescription in boxes of 20 at a suggested retail...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Genelabs sales and marketing update

GNLB posted product sales of 2.6 million for the second quarter ended June 30 compared to $400,000 in the same quarter last year. GNLB reported a net loss of $4.7 million (23 cents a share)...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Vestar Inc. sales and marketing update

Vestar Inc. (VSTR)   VSTR posted product sales of $9.1 million for the second quarter ended June 30 compared to product sales of $6.3 million in the second quarter last year. Net income was $100,000 (1...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

BioSurface Technology Inc. sales and marketing update

BSRF posted sales of $1.3 million for the second quarter ended June 30 compared to $2.1 million in the 1992 quarter. The company attributed the results to a decline in sales of its Epicel-CEA epidermal...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Calgene regulatory update

CGNE received notice of allowance from the Patent and Trademark Office for claims to DNA constructs for expression of ACC deaminase (ACCD) in plant cells. ACCD is an enzyme that blocks the normal production of...
12:00 AM, Aug 02, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Hycor sales and marketing update

HYBD, a marketer of allergy diagnostics, attributed lower revenues in the second quarter ended June 30 to tight inventory controls at major medical product distributors and a slowdown in bioreagent sales. Net income was $827,000...

Pages